Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15657210 | 0.98 | TBXAS1 (0.70) | TBXAS1 | |
| SCHEMBL15901891 | 0.98 | TBXAS1 (0.70) | TBXAS1 | |
| SCHEMBL2518958 | 0.98 | TBXAS1 (0.70) | TBXAS1 | |
| Hydrochloric Acid SCHEMBL15436986 | 0.96 | TBXAS1 (0.68) | TBXAS1 | |
| Iodide SCHEMBL810562 | 0.96 | TBXAS1 (0.68) | TBXAS1 | |
| SCHEMBL10650074 | 0.94 | TBXAS1 (0.63) | TBXAS1 | |
| SCHEMBL574077 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL15436959 | 0.84 | TBXAS1 (0.54) | TBXAS1 | |
| Iodide SCHEMBL28622555 | 0.84 | TBXAS1 (0.54) | TBXAS1 | |
| SCHEMBL28320158 | 0.84 | TBXAS1 (0.54) | TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034899-A1 | CURABLE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-02-01 | — | — | US | disclosed |
| CN-117467307-A | curable composition | 东京应化工业株式会社 | 2024-01-30 | — | — | CN | disclosed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113460-A1 | Organic Compounds | GIVAUDAN SA (CH) | 2010-05-06 | — | — | US | disclosed |
| EP-2139354-A2 | ORGANIC COMPOUNDS | Givaudan SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116339-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116339-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| US-4260552-A | INSECTICIDES, HERBICIDES | UNIROYAL, INC. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4160846-A | Method for controlling insects with tetrasubstituted organotin compounds | UNIROYAL, INC. (US) | 1979-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113460-A1 | Organic Compounds | CYP2B6, CYP2A6, CYP2A13 | TBXAS1 406/4885HMOX1 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.